Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018 ; volume:195 ; number:2 ; day:22 ; month:7 ; year:2022 ; pages:171-180 ; date:9.2022
Breast cancer research and treatment ; 195, Heft 2 (22.7.2022), 171-180, 9.2022
- Creator
-
Kaplan, Henry G.
Malmgren, Judith A.
Guo, Boya
Atwood, Mary K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-022-06678-1
- URN
-
urn:nbn:de:101:1-2022112709362523597156
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kaplan, Henry G.
- Malmgren, Judith A.
- Guo, Boya
- Atwood, Mary K.
- SpringerLink (Online service)
Other Objects (12)
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab